← Back to all signals
RESEARCH PAPER ANALYSIS

Estimating long-term care needs in data-scarce settings: a diagnostic model with evidence from MENA.

This paper develops a scalable Long-Term Care Needs Index for eight MENA countries by combining demographic ageing, disability prevalence, and transition probabilities from five major NCDs (including Parkinson's) to estimate and project care dependency through 2030.

PMID42045931
JournalPopulation health metrics
Publication Date2026-04-27
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This paper develops a scalable Long-Term Care Needs Index for eight MENA countries by combining demographic ageing, disability prevalence, and transition probabilities from five major NCDs (including Parkinson's) to estimate and project care dependency through 2030.

WHY IT MATTERS

Research significance

While it offers little mechanistic or therapeutic insight for Parkinson's research, the study is useful for strategic planning by quantifying projected care burden from PD at a population level and highlighting the need for better PD-specific, individual-level data to inform service delivery and…

ABSTRACT

Source abstract

BACKGROUND: Rapid population ageing, high burdens of non-communicable diseases (NCDs), and limited formal care systems are converging in the Middle East and North Africa (MENA) region, generating an urgent need for evidence-based long-term care (LTC) planning. However, the absence of individual-level data on care dependency hampers assessment and policy design. METHODS: We developed a population-based LTC Needs Index to estimate care dependency in data-scarce contexts. The Index integrates demographic ageing, prevalence of disability, and transition probabilities from five major NCDs (cardiovascular disease, diabetes, cancer, Alzheimer's disease, and Parkinson's disease) using standardized national and international data sources. Cross-country comparability was ensured through normalization and weighting procedures, and the model's robustness was tested using Bayesian, bootstrap, and deterministic sensitivity analyses. RESULTS: The LTC Needs Index reveals substantial heterogeneity in care dependency across eight MENA countries, ranging from approximately 3% of the total population in Oman to 22.8% in Saudi Arabia. Projections for 2024-2030 show a consistent upward trend in LTC needs, primarily driven by demographic ageing. Disability emerged as the dominant factor, accounting for 67-94% of total index values, with diabetes and cardiovascular diseases contributing most strongly in Gulf states. Sensitivity analyses confirmed the index's stability under varying assumptions. CONCLUSIONS: The LTC Needs Index offers a scalable, validated diagnostic model for estimating population-level LTC needs in data-limited settings. It highlights the need for differentiated LTC strategies reflecting the varying contributions of disability and NCDs across countries. To advance equity and precision in planning, countries should invest in nationally representative survey data on ageing, disability, and care dependency to capture intra-country inequalities. The Index provides a transferable framework applicable to other data-scarce regions seeking to strengthen long-term care systems and policy preparedness for population ageing.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic